Sverige - svenska - Läkemedelsverket (Medical Products Agency)

bgp products ab - influensavirus a/cambodia/e0826360/2020 (h3n2)-liknande stam (a/cambodia/e0826360/2020, ivr-224), ytantigen, inaktiverat; influensavirus a/victoria/2570/2019 (h1n1)pdm09-liknande stam (a/victoria/2570/2019, ivr-215), ytantigen, inaktiverat; influensavirus b/washington/02/2019-liknande strain (b/washington/02/2019, vildtyp), ytantigen, inaktiverat - injektionsvätska, suspension, förfylld spruta - influensavirus b/washington/02/2019-liknande strain (b/washington/02/2019, vildtyp), ytantigen, inaktiverat 15 mikrog aktiv substans; influensavirus a/victoria/2570/2019 (h1n1)pdm09-liknande stam (a/victoria/2570/2019, ivr-215), ytantigen, inaktiverat 15 mikrog aktiv substans; influensavirus a/cambodia/e0826360/2020 (h3n2)-liknande stam (a/cambodia/e0826360/2020, ivr-224), ytantigen, inaktiverat 15 mikrog aktiv substans - spjälkat virus eller ytantigen

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

seqirus s.r.l - influensavirus a/guangdong-maonan/swl1536/2019 (h1n1) pdm09-liknande stam (a/victoria/2454/2019 ivr-207), ytantigen, inaktiverat; influensavirus a/hong kong/2671/2019 (h3n2)-liknande stam (a/hong kong/2671/2019 ivr-208), ytantigen, inaktiverat; influensavirus b/washington/02/2019-liknande stam (b/victoria/705/2018 bvr-11), ytantigen, inaktiverat - injektionsvätska, suspension, förfylld spruta - influensavirus a/guangdong-maonan/swl1536/2019 (h1n1) pdm09-liknande stam (a/victoria/2454/2019 ivr-207), ytantigen, inaktiverat 15 mikrog aktiv substans; influensavirus b/washington/02/2019-liknande stam (b/victoria/705/2018 bvr-11), ytantigen, inaktiverat 15 mikrog aktiv substans; influensavirus a/hong kong/2671/2019 (h3n2)-liknande stam (a/hong kong/2671/2019 ivr-208), ytantigen, inaktiverat 15 mikrog aktiv substans - spjälkat virus eller ytantigen

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

seqirus s.r.l - influensavirus a/guangdong-maonan/swl1536/2019 (h1n1) pdm09-liknande stam (a/victoria/2454/2019 ivr-207), ytantigen, inaktiverat; influensavirus a/hong kong/2671/2019 (h3n2)-liknande stam (a/hong kong/2671/2019 ivr-208), ytantigen, inaktiverat; influensavirus b/washington/02/2019-liknande stam (b/victoria/705/2018 bvr-11), ytantigen, inaktiverat - injektionsvätska, suspension, förfylld spruta - influensavirus b/washington/02/2019-liknande stam (b/victoria/705/2018 bvr-11), ytantigen, inaktiverat 15 mikrog aktiv substans; influensavirus a/hong kong/2671/2019 (h3n2)-liknande stam (a/hong kong/2671/2019 ivr-208), ytantigen, inaktiverat 15 mikrog aktiv substans; influensavirus a/guangdong-maonan/swl1536/2019 (h1n1) pdm09-liknande stam (a/victoria/2454/2019 ivr-207), ytantigen, inaktiverat 15 mikrog aktiv substans; skvalen 9,75 mg adjuvans; polysorbat 80 1,175 mg adjuvans; sorbitantrioleat 1,175 mg adjuvans; citronsyra (vattenfri) 0,04 mg adjuvans; natriumcitrat (dihydrat) 0,66 mg adjuvans - spjälkat virus eller ytantigen

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

besins healthcare - estradiolhemihydrat - transdermal gel - 0,75 mg/dos - estradiolhemihydrat 0,775 mg aktiv substans; etanol, vattenfri hjälpämne

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

brown & burk ir limited - lymecyklin - kapsel, hård - 300 mg - lymecyklin 408 mg aktiv substans; propylenglykol hjälpämne - lymecyklin

Europeiska unionen - svenska - EMA (European Medicines Agency)

regeneron ireland designated activity company (dac) - cemiplimab - carcinom, squamous cell - antineoplastiska medel - cutaneous squamous cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mcscc or lacscc) who are not candidates for curative surgery or curative radiation. basal cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic basal cell carcinoma (labcc or mbcc) who have progressed on or are intolerant to a hedgehog pathway inhibitor (hhi). non-small cell lung cancerlibtayo as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (nsclc) expressing pd-l1 (in ≥ 50% tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. libtayo in combination with platinum‐based chemotherapy is indicated for the first‐line treatment of adult patients with nsclc expressing pd-l1 (in ≥ 1% of tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. cervical cancerlibtayo as monotherapy is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

opella healthcare france sas - ipratropiumbromid (monohydrat) - nässpray, lösning - 21 mikrogram/dos - bensalkoniumklorid hjälpämne; ipratropiumbromid (monohydrat) 22 mikrog aktiv substans - ipratropiumbromid

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

europharma sverige ab - ipratropiumbromid (monohydrat) - nässpray, lösning - 21 mikrogram/dos - bensalkoniumklorid hjälpämne; ipratropiumbromid (monohydrat) 22 mikrog aktiv substans - ipratropiumbromid

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

paranova läkemedel ab - ipratropiumbromid (monohydrat) - nässpray, lösning - 21 mikrogram/dos - ipratropiumbromid (monohydrat) 22 mikrog aktiv substans; bensalkoniumklorid hjälpämne - ipratropiumbromid

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

orifarm ab - ipratropiumbromid (monohydrat) - nässpray, lösning - 21 mikrogram/dos - bensalkoniumklorid hjälpämne; ipratropiumbromid (monohydrat) 22 mikrog aktiv substans - ipratropiumbromid